8-K: Annexon Reports Q3 2025 Results, Advances Key Programs

Annexon, Inc. announced its third quarter 2025 financial results and provided updates on its late-stage neuroinflammation pipeline, including GBS and GA programs.

Summary

• Cash and cash equivalents and short-term investments were $188.7 million as of September 30, 2025.
• Operating runway is extended into late first quarter 2027, covering several important milestones.
• Research and development (R&D) expenses increased to $49.7 million for the quarter ended September 30, 2025, compared to $30.1 million for the same period in 2024.
• General and administrative (G&A) expenses decreased to $7.3 million for the quarter ended September 30, 2025, compared to $9.3 million for the same period in 2024.
• Net loss was $54.9 million, or $0.37 per share, for the quarter ended September 30, 2025, compared to $34.8 million, or $0.25 per share, for the same period in 2024.
• The Tanruprubart (ANX005) GBS dossier is on track for Marketing Authorisation Application (MAA) filing in Europe in January 2026.
• The registrational Phase 3 ARCHER II trial for Vonaprument (ANX007) in Dry AMD with Geographic Atrophy (GA) completed enrollment early in July 2025, with topline data expected in the second half of 2026.
• The ANX1502 Cold Agglutinin Disease (CAD) Proof of Concept study is ongoing, with completion anticipated in 2026.

Sentiment

Score: 6

Explanation: While financial losses increased and cash decreased, the company successfully extended its cash runway into 2027 and reported significant clinical and regulatory progress for its late-stage pipeline, including on-track MAA filing for GBS and early enrollment completion for GA Phase 3, which are strong operational positives. The increased R&D spend is tied to these advancements.

Positives

• Operating runway is extended into late first quarter 2027, covering several important milestones including global GBS filings, GA Phase 3 data, and ANX1502 autoimmune proof of concept data.
• Tanruprubart GBS dossier is on track for EU MAA filing in January 2026, positioning it as a potential first approved targeted and fast-acting therapy for GBS, a disease affecting ~150,000 people worldwide annually.
• Vonaprument ARCHER II pivotal data for Dry AMD with GA is on track for H2 2026, with potential to be the first approved vision-sparing therapy for eight million GA patients worldwide.
• ANX1502 CAD Proof of Concept study is ongoing, with potential to be the only oral C1s inhibitor for multiple neuroinflammatory autoimmune diseases.
• General and administrative expenses declined to $7.3 million in Q3 2025 from $9.3 million in Q3 2024, reflecting ongoing corporate efficiencies and disciplined resource prioritization.
• The registrational Phase 3 ARCHER II trial completed enrollment early in July 2025, exceeding enrollment targets for a total of 659 GA patients.
• Vonaprument was selected by the European Medicines Agency (EMA) for the exclusive Product Development Coordinator (PDC) pilot, assisting with regulatory interactions.
• Positive engagements with the FDA and EMA support the established vonaprument ARCHER II global regulatory approval path for protection of vision in patients with GA.
• Further analyses of the Phase 2 ARCHER trial reinforced that vonaprument treatment showed a 73% reduction in risk of vision loss measured by the gold-standard BCVA 15-letter loss endpoint.

Negatives

• Net loss increased to $54.9 million in Q3 2025 from $34.8 million in Q3 2024.
• Net loss per share increased to $0.37 in Q3 2025 from $0.25 in Q3 2024.
• Research and development expenses increased to $49.7 million in Q3 2025 from $30.1 million in Q3 2024, primarily due to the advancement of the Phase 3 ARCHER II trial and investments toward tanruprubart global filings.
• Cash and cash equivalents and short-term investments decreased from $312.017 million as of December 31, 2024, to $188.7 million as of September 30, 2025.

Risks

• The final results from the Phase 3 ARCHER II trial may not be positive.
• The company has a history of net operating losses.
• The company's ability to obtain necessary capital to fund its clinical programs is uncertain.
• There is potential for delays in clinical trials, including if the FDA and comparable foreign regulatory authorities do not accept data from clinical trials for product candidates outside the United States.
• Some of the company's product candidates are in early stages of clinical development.
• Public health crises could affect the company's clinical programs and business operations.
• The company's ability to obtain regulatory approval of and successfully commercialize its product candidates is not guaranteed.
• Product candidates may have undesirable side effects or other properties.
• The company relies on third-party suppliers and manufacturers.
• The outcomes of any future collaboration agreements are uncertain.
• The company's ability to adequately maintain intellectual property rights for its product candidates is a risk.

Future Outlook

The company expects to fund operations and anticipated milestones into late first quarter 2027. Key milestones include the tanruprubart global GBS filings, vonaprument topline GA Phase 3 data, and ANX1502 autoimmune proof of concept data. The MAA submission for tanruprubart in GBS is expected in January 2026, and topline Phase 3 ARCHER II data for vonaprument in GA is anticipated in the second half of 2026. The ANX1502 CAD study completion is expected in 2026.

Management Comments

• "We're pleased with the focused execution of our business strategy across our late-stage neuroinflammation platform, and the strong momentum we've built over 2025 heading into a meaningful 2026." Douglas Love, President and Chief Executive Officer of Annexon.
• "Our next-generation complement inhibitor candidates continue to demonstrate the power of stopping neuroinflammation at its source, enabling multiple programs advancing toward key near-term milestones." Douglas Love, President and Chief Executive Officer of Annexon.
• "Our registrational Guillain-Barr Syndrome program is on track for EU Marketing Authorisation Application (MAA) submission in January 2026, positioning it to become the first targeted therapy for GBS, a disease that annually affects 150,000 people worldwide." Douglas Love, President and Chief Executive Officer of Annexon.
• "Dialogue with the FDA is also ongoing regarding the generalizability package supporting the U.S. Biologics License Application (BLA) submission." Douglas Love, President and Chief Executive Officer of Annexon.
• "Our registrational Phase 3 trial for vonaprument in GA is on track to deliver topline data in the second half of 2026. The study is designed to confirm the significant vision preservation observed in our Phase 2 trial and benefit the eight million people affected by GA worldwide." Douglas Love, President and Chief Executive Officer of Annexon.
• "Finally, we are building on the early learnings from our ANX1502 program, the first and only clinical stage oral inhibitor of C1s. We've observed targeted drug levels in fasted CAD patients, and we continue to dose to deepen our understanding of ANX1502's profile, anticipating study completion in 2026." Douglas Love, President and Chief Executive Officer of Annexon.
• "With a prioritized capital plan, our runway is extended into 2027 through each of the above anticipated milestones." Douglas Love, President and Chief Executive Officer of Annexon.
• "Overall, Annexon is uniquely positioned to drive near-term value while pursuing additional opportunities to achieve our mission of helping millions of patients suffering from devastating neuroinflammatory diseases." Douglas Love, President and Chief Executive Officer of Annexon.

Industry Context

Annexon is advancing a late-stage clinical platform targeting neuroinflammation, a significant area in biopharmaceuticals. Their focus on complement inhibition (C1q and C1s) positions them in a competitive landscape for rare and common neuroinflammatory diseases like GBS, GA, and CAD. The potential for first-in-class or first-approved targeted therapies in GBS and vision-sparing therapy in GA could be disruptive, addressing large unmet medical needs. The development of an oral C1s inhibitor (ANX1502) also represents a novel approach in autoimmune conditions, potentially offering a more convenient treatment option compared to existing or developing injectable therapies.

Comparison to Industry Standards

• Tanruprubart (ANX005) for GBS is positioned to be the first approved targeted and fast-acting therapy for GBS, a disease affecting approximately 150,000 people worldwide annually, where there are currently no FDA-approved therapies and limited evidence of effectiveness from current standards of care (SOC) like IVIg or plasma exchange.
• Vonaprument (ANX007) for Dry AMD with GA has the potential to be the first approved vision-sparing therapy for the treatment of eight million GA patients worldwide. The ARCHER II trial is the first study to evaluate a therapy for dry AMD with GA targeting visual function as the primary endpoint (BCVA 15-letter loss), which is considered a gold standard. Phase 2 data showed a 73% reduction in risk of vision loss, which is a strong signal compared to the lack of approved vision-preserving therapies.
• ANX1502 for Autoimmune Conditions (CAD) has the potential to be the only oral C1s inhibitor, offering a disruptive advantage of oral administration compared to existing or developing antibody-based complement inhibitors which are typically infused.

Stakeholder Impact

• Shareholders: Potential for significant value creation if late-stage programs achieve regulatory approval and commercialization, but also continued dilution risk due to ongoing net losses and potential future capital needs.
• Patients (GBS): Potential for a first-in-class targeted and fast-acting therapy, addressing a significant unmet medical need for approximately 150,000 people worldwide annually.
• Patients (GA): Potential for a first-in-class vision-sparing therapy for approximately 8 million people worldwide affected by dry AMD with GA.
• Patients (CAD/Autoimmune): Potential for a convenient oral C1s inhibitor, offering a new treatment option.
• Employees: Continued employment and focus on advancing clinical programs.

Next Steps

• Tanruprubart MAA submission in Europe expected in January 2026.
• Update on FDA BLA submission for tanruprubart upon further regulatory dialogue.
• Initial FORWARD study data for tanruprubart anticipated in 2026.
• Topline Phase 3 ARCHER II trial data for vonaprument expected in the second half of 2026.
• ANX1502 program update upon CAD study completion in 2026.
• Continued ongoing discussions with pharmaceutical companies on collaboration opportunities to commercialize tanruprubart for GBS in various geographies.

Key Dates

Recommendation

While the financial results show increased losses and reduced cash, the company has successfully extended its cash runway into 2027, covering several critical clinical milestones. The progress in the late-stage pipeline, particularly the on-track MAA filing for GBS and early enrollment completion for the GA Phase 3 trial, represents significant operational achievements and potential future value drivers. However, the increased net loss and R&D expenses, coupled with the inherent risks of clinical development and regulatory approval, warrant a "hold" recommendation until further clarity on clinical outcomes and commercialization prospects emerges. The stock is likely to be volatile based on upcoming data readouts.

Keywords

Annexon, ANNX, biopharmaceutical, neuroinflammation, Guillain-Barr Syndrome, GBS, Geographic Atrophy, GA, Dry AMD, Cold Agglutinin Disease, CAD, C1q inhibitor, C1s inhibitor, clinical trials, Phase 3, MAA, BLA, financial results, Q3 2025, tanruprubart, vonaprument, ANX005, ANX007, ANX1502, complement inhibition